EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial

Philip N Newsome iD, Arun J Sanyal iD, Kristiane A Engebretsen, Iris Kliers, Laura Østergaard, Denise Vanni, Elisabetta Bugianesi, Mary E Rinella, Michael Roden iD, Vlad Ratziu iD

Alimentary Pharmacology & Therapeutics · 2024-12 · 60 (11-12) · 1525-1533

DOI: 10.1111/apt.18331 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 16.10.2024. Verfasst von Philip N Newsome und 9 weiteren Autor:innen. Beteiligte Einrichtung: Roger Williams Institute of Liver Studies, Faculty of Life Sciences and Medicine, King's College London and King's College Hospital, London, UK. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 152-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Semaglutide, a glucagon‐like peptide‐1 receptor agonist, has demonstrated potential beneficial effects in metabolic dysfunction‐associated steatohepatitis (MASH).

Aims

To describe the trial design and baseline characteristics of the ‘Effect of Semaglutide in Subjects with Non‐cirrhotic Non‐alcoholic Steatohepatitis’ (ESSENCE) trial (NCT04822181).

Methods

ESSENCE is a two‐part, phase 3, randomised, multicentre trial evaluating the effect of subcutaneous semaglutide 2.4 mg in participants with biopsy‐proven MASH and fibrosis stage 2 or 3. The primary objective of Part 1 is to demonstrate that semaglutide improves liver histology compared with placebo. The two primary endpoints are: resolution of steatohepatitis and no worsening of liver fibrosis, and improvement in liver fibrosis and no worsening of steatohepatitis. The Part 2 objective is based on clinical outcomes. The current work reports baseline characteristics of the first 800 randomised participants which includes demographics, laboratory parameters, liver histology, non‐invasive tests and presence of metabolic dysfunction‐associated steatotic liver disease (MASLD) cardiometabolic criteria.

Results

Of 800 participants, 250 (31.3%) had fibrosis stage 2 and 550 (68.8%) had fibrosis stage 3. In the overall population, mean (standard deviation [SD]) age was 56 (11.6) years, 57.1% were female, mean (SD) body mass index was 34.6 (7.2) kg/m 2 , 55.5% had type 2 diabetes and > 99% had at least one MASLD cardiometabolic criterion according to the published definition.

Conclusion

The ESSENCE baseline population includes participants with clinically significant fibrosis stages 2 and 3. Although MASLD cardiometabolic criteria were not a requirement for study enrolment, almost all participants (> 99%) had at least one MASLD cardiometabolic criterion. Trial Registration NCT04822181

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesNon-alcoholic Fatty Liver DiseaseAdultAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodHypoglycemic AgentsLiverLiver CirrhosisTreatment OutcomeMulticenter Studies as TopicClinical Trials, Phase III as TopicRandomized Controlled Trials as TopicSemaglutide

Stichwörter der Autor:innen

ESSENCEMASHMASLDsemaglutide

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsSemaglutide

Autor:innen und Institutionen

  • Roger Williams Institute of Liver Studies, Faculty of Life Sciences and Medicine, King's College London and King's College Hospital, London, UK.
  • College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
  • VCU School of Medicine, Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Richmond, Virginia, USA.
  • Novo Nordisk A/S, Copenhagen, Denmark.
  • Department of Medical Sciences, University of Turin, Turin, Italy.
  • Division of Gastroenterology, Hepatology and Nutrition, University of Chicago, Chicago, Illinois, USA.

ORCID-Profile: Philip N Newsome, Arun J Sanyal, Michael Roden, Vlad Ratziu

Förderung

  • Novo Nordisk A/S

Zitieren

APA

Newsome, P. N., Sanyal, A. J., Engebretsen, K. A., Kliers, I., Østergaard, L., Vanni, D., Bugianesi, E., Rinella, M. E., Roden, M., & Ratziu, V. (2024). Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. Alimentary Pharmacology & Therapeutics, 60(11-12), 1525-1533. https://doi.org/10.1111/apt.18331

Vancouver

Newsome PN, Sanyal AJ, Engebretsen KA, Kliers I, Østergaard L, Vanni D, et al. Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. Alimentary Pharmacology & Therapeutics. 2024;60(11-12):1525-1533. doi:10.1111/apt.18331

BibTeX
@article{Newsome2024,
  author = {Newsome, Philip N and Sanyal, Arun J and Engebretsen, Kristiane A and Kliers, Iris and Østergaard, Laura and Vanni, Denise and Bugianesi, Elisabetta and Rinella, Mary E and Roden, Michael and Ratziu, Vlad},
  title = {Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  volume = {60},
  number = {11-12},
  pages = {1525--1533},
  doi = {10.1111/apt.18331}
}
Kostenlos starten →